

# DIN EN ISO 14155:2021-05 (E)

## Clinical investigation of medical devices for human subjects - Good clinical practice (ISO 14155:2020)

---

<b>Contents</b>		<b>Page</b>
<b>European foreword</b> .....		<b>5</b>
<b>Annex ZA (informative) Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered</b> .....		<b>7</b>
<b>Annex ZB (informative) Relationship between this European Standard and the essential requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered</b> .....		<b>9</b>
<b>Foreword</b> .....		<b>11</b>
<b>1</b>	<b>Scope</b> .....	<b>12</b>
<b>2</b>	<b>Normative references</b> .....	<b>12</b>
<b>3</b>	<b>Terms and definitions</b> .....	<b>12</b>
<b>4</b>	<b>Summary of good clinical practice (GCP) principles</b> .....	<b>20</b>
<b>5</b>	<b>Ethical considerations</b> .....	<b>21</b>
5.1	General.....	21
5.2	Improper influence or inducement.....	21
5.3	Compensation and additional health care.....	21
5.4	Registration in publicly accessible database.....	22
5.5	Responsibilities.....	22
5.6	Communication with the ethics committee (EC).....	22
5.6.1	General.....	22
5.6.2	Initial EC submission.....	22
5.6.3	Information to be obtained from the EC.....	23
5.6.4	Continuing communication with the EC.....	23
5.6.5	Continuing information to be obtained from the EC.....	23
5.7	Vulnerable populations.....	23
5.8	Informed consent.....	24
5.8.1	General.....	24
5.8.2	Process of obtaining informed consent.....	24
5.8.3	Special circumstances for informed consent.....	25
5.8.4	Information to be provided to the subject.....	26
5.8.5	Informed consent signature.....	28
5.8.6	New information.....	28
<b>6</b>	<b>Clinical investigation planning</b> .....	<b>28</b>
6.1	General.....	28
6.2	Risk management.....	29
6.2.1	General.....	29
6.2.2	Investigational device including clinical procedure risks and their disclosure.....	29
6.2.3	Clinical investigation process.....	29
6.3	Justification for the design of the clinical investigation.....	30
6.4	Clinical investigation plan (CIP).....	30
6.5	Investigator's brochure (IB).....	30
6.6	Case report forms (CRFs).....	31
6.7	Monitoring plan.....	31
6.8	Investigation site selection.....	32
6.9	Agreement(s).....	32
6.10	Labelling.....	32
6.11	Data monitoring committee (DMC).....	32

<b>7</b>	<b>Clinical investigation conduct</b>	<b>33</b>
7.1	General	33
7.2	Investigation site initiation	33
7.3	Investigation site monitoring	33
7.4	Adverse events and device deficiencies	33
	7.4.1 Signals requiring immediate action	33
	7.4.2 Adverse events	34
	7.4.3 Device deficiencies	34
	7.4.4 Risk assessment process for potentially unacceptable risks	34
7.5	Clinical investigation documents and documentation	35
	7.5.1 Amendments	35
	7.5.2 Subject identification log	35
	7.5.3 Source documents	36
7.6	Additional members of the investigation site team	36
7.7	Subject privacy and confidentiality of data	36
7.8	Document and data control	36
	7.8.1 Traceability of documents and data	36
	7.8.2 Recording of data	36
	7.8.3 Electronic clinical data systems	37
7.9	Investigational device accountability	38
7.10	Accounting for subjects	38
7.11	Auditing	38
<b>8</b>	<b>Suspension, termination, and close-out of the clinical investigation</b>	<b>39</b>
8.1	Completion of the clinical investigation	39
8.2	Suspension or premature termination of the clinical investigation	39
	8.2.1 Procedure for suspension or premature termination	39
	8.2.2 Procedure for resuming the clinical investigation after temporary suspension	40
8.3	Routine close-out	40
8.4	Clinical investigation report	41
8.5	Risk assessment and conclusions	41
8.6	Document retention	42
<b>9</b>	<b>Responsibilities of the sponsor</b>	<b>42</b>
9.1	Clinical quality management	42
9.2	Clinical investigation planning and conduct	42
	9.2.1 Selection and training of clinical personnel	42
	9.2.2 Preparation of documents and materials	43
	9.2.3 Conduct of clinical investigation	44
	9.2.4 Monitoring	44
	9.2.5 Safety evaluation and reporting	47
	9.2.6 Clinical investigation close-out	48
9.3	Outsourcing of duties and functions	48
9.4	Communication with regulatory authorities	48
<b>10</b>	<b>Responsibilities of the principal investigator</b>	<b>49</b>
10.1	General	49
10.2	Qualification of the principal investigator	49
10.3	Qualification of investigation site	49
10.4	Communication with the EC	49
10.5	Informed consent process	50
10.6	Compliance with the CIP	50
10.7	Medical care of subjects	51
10.8	Safety reporting	52

<b>Annex A (normative) Clinical investigation plan (CIP)</b> .....	<b>53</b>
<b>Annex B (normative) Investigator's brochure (IB)</b> .....	<b>62</b>
<b>Annex C (informative) Case report forms (CRFs)</b> .....	<b>65</b>
<b>Annex D (normative) Clinical investigation report</b> .....	<b>67</b>
<b>Annex E (informative) Essential clinical investigation documents</b> .....	<b>72</b>
<b>Annex F (informative) Adverse event categorization</b> .....	<b>79</b>
<b>Annex G (informative) EC responsibilities</b> .....	<b>81</b>
<b>Annex H (informative) Application of ISO 14971 to clinical investigations</b> .....	<b>85</b>
<b>Annex I (informative) Clinical development stages</b> .....	<b>86</b>
<b>Annex J (informative) Clinical investigation audits</b> .....	<b>91</b>
<b>Bibliography</b> .....	<b>94</b>